Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

BACKGROUND. Relapsed or refractory mantle cell lymphoma (MCL) has a poor prognosis. The best outcome is achieved in patients who have a partial or complete response to salvage treatment and proceed to allogeneic stem cell transplant. PATIENTS AND METHODS. Twenty‐one patients were given a combination...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Lee, Hun Ju, Romaguera, Jorge E., Feng, Lei, Desai, Aakash P., Zhang, Liang, Fanale, Michelle, Samaniego, Felipe, Hagemeister, Fredrick B., Fayad, Luis E., Rodriguez, Maria A., Medeiros, Jeffrey L., Hartig, Kimberly, Nomie, Krystle, Ahmed, Makhdum, Badillo, Maria, Ye, Haige, Oki, Yasuhiro, Lin, Pei, Nastoupil, Loretta, Westin, Jason, Wang, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2017
Témata:
Hematologic Malignancies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423503/
https://ncbi.nlm.nih.gov/pubmed/28408615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0328
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky